Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Cancer Disparities Progress Report and what oncologists can do to combat them.
Commentary|Articles|February 10, 2025
Supplements and Featured Publications
- Perspectives on FDA Oncology Approvals and Withdrawals That Shaped 2024: A Year in Review Roundup
- Volume 1
- Issue 1
Experts Comment on the GI/GU Cancer FDA Approvals From 2024
Author(s)Megan Hollasch
Fact checked by: Caroline Seymour
Experts provide insights on the 2024 FDA approvals in the gastrointestinal and genitourinary fields in this list featuring all the regulatory decisions.
Advertisement
Advertisement
The gastrointestinal (GI) and genitourinary (GU) fields saw over 10 FDA approvals add to their paradigms in 2024, and throughout the year oncologists sat down with OncLive to detail the significance of these regulatory decisions.
Related to this article
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.
Paul E. Oberstein, MD, discusses data for an autogene cevumeran–based regimen in pancreatic ductal adenocarcinoma.
Maurie Markman, MD, discusses conflicts of interest in cancer care.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
Advertisement
Advertisement